M. E. Vega-Villegas

1.6k total citations · 1 hit paper
17 papers, 1.2k citations indexed

About

M. E. Vega-Villegas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, M. E. Vega-Villegas has authored 17 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Surgery. Recurrent topics in M. E. Vega-Villegas's work include Head and Neck Cancer Studies (7 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (7 papers). M. E. Vega-Villegas is often cited by papers focused on Head and Neck Cancer Studies (7 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (7 papers). M. E. Vega-Villegas collaborates with scholars based in Spain, Italy and Germany. M. E. Vega-Villegas's co-authors include M. López-Brea, Fernando Rivera, O. Kisker, Fernando Rivera, Christophe Borg, Alberto Sobrero, Heinz‐Josef Lenz, Howard A. Burris, Cathy Eng and Joan Maurel and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

M. E. Vega-Villegas

16 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

2008 726 citations Alberto Sobrero, Joan Maurel et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by M. E. Vega-Villegas

Since Specialization

Citations

This map shows the geographic impact of M. E. Vega-Villegas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. E. Vega-Villegas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. E. Vega-Villegas more than expected).

Fields of papers citing papers by M. E. Vega-Villegas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. E. Vega-Villegas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. E. Vega-Villegas. The network helps show where M. E. Vega-Villegas may publish in the future.

Co-authorship network of co-authors of M. E. Vega-Villegas

This figure shows the co-authorship network connecting the top 25 collaborators of M. E. Vega-Villegas. A scholar is included among the top collaborators of M. E. Vega-Villegas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. E. Vega-Villegas. M. E. Vega-Villegas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study 2009 ·Annals of Oncology ·Josep Tabernero, Fortunato Ciardiello, Fernando Rivera, Edith Rodríguez-Braun, Francisco Javier Ramos, Erika Martinelli, M. E. Vega-Villegas, Susana Roselló, (unknown), O. Kisker, Teresa Macarulla, José Baselga, Andrés Cervantes	72
2	Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma 2009 ·International Journal of Radiation OncologyBiologyPhysics ·Fernando Rivera, Maica Galán, Josep Tabernero, Andrés Cervantes, M. E. Vega-Villegas, Javier Gállego, (unknown), (unknown), Alfredo Carrato, P. Escudero, Bartomeu Massutí, Vicente Alonso-Orduña, (unknown), A. Sáenz, J. Giralt, (unknown), Antonio Antón, Enrique Aranda	31
3	Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial 2009 ·Expert Review of Anticancer Therapy ·Fernando Rivera, Almudena García‐Castaño, (unknown), M. E. Vega-Villegas, (unknown)	90
4	Cetuximab, its clinical use and future perspectives 2008 ·Anti-Cancer Drugs ·Fernando Rivera, M. E. Vega-Villegas, M. López-Brea	49
5	Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer 2008 ·Acta Oncologica ·Fernando Rivera, M. E. Vega-Villegas, Carlos López, (unknown), Antonio Rubio, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yolanda Blanco, (unknown), Sara López‐Tarruella, Jaime Sanz‐Ortiz	0
6	Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer 2008 ·Clinical & Translational Oncology ·Antonio Jimeno, Cristina Grávalos, P. Escudero, Isabel Sevilla, M. E. Vega-Villegas, Vicente Alonso, (unknown), Rocio García‐Carbonero, (unknown), Rámón Colomer, H. Cortés-Funes	9
7	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer breakdown → 2008 ·Journal of Clinical Oncology ·Alberto Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif Abubakr, Manfred P. Lutz, M. E. Vega-Villegas, Cathy Eng, E.U. Steinhauer, Jana Prausová, Heinz‐Josef Lenz, Christophe Borg, Gary Middleton, H. Kröning, Gabriele Luppi, O. Kisker, Angela Zubel, Christiane Langer, Justin Kopit, Howard A. Burris	726
8	Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC) 2007 ·Cancer Chemotherapy and Pharmacology ·Fernando Rivera, M. E. Vega-Villegas, M. López-Brea, Dolores Isla, Marta Mayorga, (unknown), Antonio Rubio, (unknown), (unknown), (unknown), (unknown), José Mayordomo, (unknown), (unknown), Jaime Sanz‐Ortiz	8
9	Chemotherapy of advanced gastric cancer 2007 ·Cancer Treatment Reviews ·Fernando Rivera, M. E. Vega-Villegas, M. López-Brea	115
10	3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules 2007 ·European Journal of Cancer Supplements ·Fortunato Ciardiello, Andrés Cervantes, M. E. Vega-Villegas, E. Casado, Edith Rodríguez-Braun, Erika Martinelli, (unknown), José Baselga, O. Kisker, Josep Tabernero	4
11	Long term results of a phase II trial of Induction Chemotherapy with Uracil-Ftegafur (UFT), Vinorelbine and Cisplatin (UFTVP) followed by Radiotherapy concomitant with UFT and Carboplatin (RT/UFTJ) in Non-Resectable Locally Advanced (Stage IV-B) Squamous Cell Head and Neck Carcinoma and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia 2007 ·Clinical & Translational Oncology ·Fernando Rivera, M. E. Vega-Villegas, M. López-Brea, Almudena García‐Castaño, Ana De Juan, Francisco Javier Ramos, Antonio Collado, (unknown), Antonio Rubio, (unknown), (unknown), Marta Mayorga, Jaime Sanz‐Ortiz	3
12	Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment 2007 ·Journal of Clinical Oncology ·Cristina Grávalos, Javier Sastre, Enrique Aranda, Bartomeu Massutí, M. E. Vega-Villegas, Ana María Gómez, M. Varella-Garcia, Antonio Jimeno, (unknown), María Jesús Cancelo Hidalgo	4
13	Long term results of a phase II trial of Induction Chemotherapy with Uracil-Ftegafur (UFT), Vinorelbine and Cisplatin (UFTVP) followed by Radiotherapy concomitant with UFT and Carboplatin (RT/UFTJ) in Non-Resectable Locally Advanced (Stage IV-B) Squamous Cell Head and Neck Carcinoma 2007 ·Clinical & Translational Oncology ·Fernando Rivera, M. E. Vega-Villegas, M. López-Brea, Almudena García‐Castaño, Ana De Juan, Francisco Javier Ramos, Antonio Collado, (unknown), Antonio Rubio, (unknown), (unknown), Marta Mayorga, Jaime Sanz‐Ortiz	1
14	A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Matilde Navarro, E. Dotor, Fernando Rivera, Pedro Sánchez‐Rovira, M. E. Vega-Villegas, Andrés Cervantes, Jose Luis Monteserin Garcia, (unknown), Enrique Aranda	54
15	Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME) 2006 ·Journal of Clinical Oncology ·J. B. Vermorken, Ricard Mesı́a, M. E. Vega-Villegas, Éva Remenár, Ricardo Hitt, Andrzej Kawecki, Sylvie Rottey, (unknown), J. Erfán, Nadia Amellal	17
16	Phase II trial of preoperative irinotecan-cisplatin (IC) followed by concurrent IC and radiotherapy (IC/RT) for locally advanced gastric and esophago-gastric junction adenocarcinoma (LA-G/EGJ-A) 2006 ·Journal of Clinical Oncology ·M. E. Vega-Villegas, (unknown), Javier Gállego, Andrés Cervantes, P. Escudero, Josep Tabernero, Bartomeu Massutí, Vicente Alonso-Orduña, (unknown), Fernando Rivera	1
17	Long‐Term Results of a Phase II Trial of Induction Chemotherapy with Uracil‐Ftegafur (UFT), Vinorelbine, and Cisplatin (UFTVP) followed by Radiotherapy Concomitant with UFT and Carboplatin (RT/UFTJ) in a Primary Site Preservation Setting for Resectable Locally Advanced Squamous Cell Carcinoma of Larynx and Hypopharynx 2004 ·The Laryngoscope ·Fernando Rivera, M. E. Vega-Villegas, (unknown), Almudena García‐Castaño, Ana De Juan, Antonio Collado, (unknown), Antonio Rubio, (unknown), (unknown), Jaime Sanz‐Ortiz	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact